Floatz logo

Rivaroxaban

Atrial Fibrillation

VA Office of Research and DevelopmentSmall moleculePhase 4 / ApprovedActive
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
77/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Atrial Fibrillation cohort.

Asset / SponsorPhaseRating
Edoxaban
National Taiwan University Hospital
Phase 4A
Dabigatran
Pfizer
Phase 4BBB
Apixaban
Regeneron Pharmaceuticals
Phase 4BBB
WARFARIN
Pfizer
Phase 4BBB
Acetylsalicylic Acid
Yonsei University
Phase 4BBB

View all 40 →

Same molecule, other indications

Rivaroxaban is also rated in:

hemorrhagic diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
thrombotic diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
coronary artery disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →